Breast Cancer Research

Table 3 Cooperation of p53 with other transgenes in mammary tumorigenesis

From: Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer?

		Mammary tumor
Transgene	Trp53 genotype	Occurrence	Latency	Tumor Trp53 status	Features	References
Brca1 ^+/-	+/+	No				[37]
	-/-	10%				[37]
Brca1 ^Ko/Co	+/+	Yes	10–13 months	Mutations		[38]
	+/-	Accelerated	6–8 months	80% LOH		[38]
Brca2 ^Co/Co	+/+	No				[21]
	+/-	Yes	360 days	100% LOH		[21]
	-/-	Accelerated	181 days			[21]
MMTV-neu	Wild type	Yes	234 days	Mutations	Euploid	[40]
	R172H	Accelerated	154 days		Aneuploid	[40]
WAP-DES	Wild type	Yes	21 months		Euploid	[41]
	R172H	Accelerated	14 months		Aneuploid	[41]
MMTV-Wnt1	+/+	Yes	22.5 weeks		Euploid	[42]
	+/-	Yes (no acceleration)	23.0 weeks	50% LOH		[42]
	-/-	Accelerated	11.5 weeks	Aneuploid, ↑ proliferation		[42]
					Less differentiated	[47]
MMTV-ras	+/+	Yes, and salivary tumors	8.5 months	No mutations		[43]
	+/-	Accelerated	6.3 months	No LOH, no mutations		[43]
	-/-	Few		↑ Aneuploidy, ↑ proliferation		[43]
		Salivary tumors dominate				[43]
MMTV/c-myc	+/+	Yes			Aneuploid	[51]
	+/-	Few		25% LOH	Aneuploid	[51]
	+/-	Lymphomas dominate		90% LOH		[51]

LOH, loss of heterozygosity; MMTV, mouse mammary tumor virus; WAP, whey acidic protein; WAP-DES = WAP-des(1-3)insulin-like growth factor-I transgene.

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com